English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The n may vary slightly for the end points at each time point. For Week 24, the n represents the number of subjects randomised at baseline in the subset; lastobservation-carried-forward methodology and non-responder imputation rule were applied to subjects who early escaped at week 16 or had missing value at week 24 for continuous data and binary response, respectively. For week 52, the n represents the number of subjects randomised to APR at baseline in the subset, with an outcome measure at week 52. For week 156, the n represents the number of subjects who were randomised to APR (at baseline, week 16, or Week 24), with an outcome measure at week 156. P<0.05; xP<0.0001 vs. placebo, based on an analysis of covariance model for the change from baseline, with treatment group, baseline DMARD use (yes/no), and study as factors and baseline value as the covariate, and the Cochran-Mantel-Haenszel test for binary response, adjusting for baseline DMARD use and study. PtGA, APR vs. placebo at Week 24: P1⁄40.0590. HAQ-DI1⁄4Health Assessment Questionnaire-Disability Index score; SF36v2 PF1⁄436-item Short-Form Health Survey version 2 Physical Functioning domain score; VAS1⁄4visual analog scale; FACIT-F1⁄4Functional Assessment of Chronic Illness Therapy-Fatigue score; PtGA1⁄4Patient’s Global Assessment of Disease Activity; PhGA1⁄4Physician’s Global Assessment of Disease Activity; mPsARC1⁄4modified Psoriatic Arthritis Response Criteria; DMARD1⁄4disease-modifying anti-rheumatic drug.

rheumatology

166 Long-term (156-week) improvements in dactylitis and enthesitis with apremilast inpsoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database